



2nd Edition

# M48

## Laboratory Detection and Identification of Mycobacteria

This guideline provides recommendations for medical mycobacteriology laboratories on the optimal approach for diagnosis of mycobacterial infections.

.....  
A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the *CLSI Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@clsi.org](mailto:standard@clsi.org)

M48, 2nd ed.  
September 2018  
Replaces M48-A

---

## Laboratory Detection and Identification of Mycobacteria

Betty A. Forbes, PhD, D(ABMM), F(AAM)  
Melissa B. Miller, PhD, D(ABMM), F(AAM)  
Niaz Banaei, MD  
Barbara A. Brown-Elliott, MS, MT(ASCP)SM  
Sanchita Das, MD, D(ABMM)  
Max Salfinger, MD, F(IDSA), F(AAM)  
Meenu K. Sharma, PhD  
Akos Somoskovi, MD, PhD, ScD  
Julie Tans-Kersten, MS, BSMT(ASCP)  
Fred C. Tenover, PhD, D(ABMM), F(AAM), F(IDSA)  
David Warshauer, PhD, D(ABMM)  
Adrian M. Zelazny, PhD, D(ABMM)

### Abstract

Clinical and Laboratory Standards Institute guideline M48—*Laboratory Detection and Identification of Mycobacteria* covers topics related to laboratory diagnosis of mycobacterial infections, including safety and risk assessment, referrals, clinical significance, acceptable specimen types, specimen collection, transport, and storage, specimen processing methods, microscopy for direct detection, molecular methods for directly detecting mycobacteria in patient specimens, culture methods, contamination issues, reporting, quality control, and conventional identification methods as they relate to mass spectrometry and genotypic procedures. Recommendations for managing the unique challenges associated with the increasing incidence of *Mycobacterium tuberculosis* and nontuberculous mycobacteria infections are included.

Clinical and Laboratory Standards Institute (CLSI). *Laboratory Detection and Identification of Mycobacteria*. 2nd ed. CLSI guideline M48 (ISBN 978-1-68440-019-5 [Print]; ISBN 978-1-68440-020-1 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2018.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).

Copyright ©2018 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Laboratory Detection and Identification of Mycobacteria*. 2nd ed. CLSI guideline M48. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

### **Previous Editions:**

February 2007, May 2008

ISBN 978-1-68440-019-5 (Print)  
ISBN 978-1-68440-020-1 (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

Volume 38, Number 18

## Committee Membership

### Consensus Council

**Dennis J. Ernst, MT(ASCP),  
NCPT(NCCT)  
Chairholder  
Center for Phlebotomy Education  
USA**

**Mary Lou Gantzer, PhD, FACB  
Vice-Chairholder  
USA**

J. Rex Astles, PhD, FACB, DABCC  
Centers for Disease Control and  
Prevention  
USA

Lucia M. Berte, MA, MT(ASCP)SBB,  
DLM, CQA(ASQ)CMQ/OE  
Laboratories Made Better!  
USA

Karen W. Dyer, MT(ASCP), DLM  
Centers for Medicare & Medicaid Services  
USA

Thomas R. Fritsche, MD, PhD, FCAP,  
FIDSA  
Marshfield Clinic  
USA

Loralie J. Langman, PhD, DABCC, FACB,  
F-ABFT  
Mayo Clinic  
USA

Ross J. Molinaro, PhD, MLS(ASCP)CM,  
DABCC, FACB  
Siemens Healthcare Diagnostics, Inc.  
USA

James R. Petisce, PhD  
BD Diagnostic Systems  
USA

Andrew Quintenz  
Bio-Rad Laboratories, Inc.  
USA

Robert Rej, PhD  
New York State Department of  
Health – Wadsworth Center  
USA

Zivana Tezak, PhD  
FDA Center for Devices and  
Radiological Health  
USA

### Document Development Committee on Laboratory Detection and Identification of Mycobacteria

**Betty A. Forbes, PhD, D(ABMM),  
F(AAM)  
Chairholder  
Medical College of Virginia Hospital  
USA**

**Melissa B. Miller, PhD, D(ABMM),  
F(AAM)  
Vice-Chairholder  
UNC School of Medicine  
USA**

**Julie Tans-Kersten, MS,  
BSMT(ASCP)  
Committee Secretary  
Wisconsin Division of Public Health  
Tuberculosis Program  
USA**

Niaz Banaei, MD  
Stanford Health Care  
USA

Barbara A. Brown-Elliott, MS,  
MT(ASCP)SM  
University of Texas Health Science Center  
at Tyler  
USA

Max Salfinger, MD, F(IDSA), F(AAM)  
National Jewish Health  
USA

Akos Somoskovi, MD, PhD, ScD  
Intellectual Ventures Laboratory, Global  
Good Fund  
USA

Fred C. Tenover, PhD, D(ABMM),  
F(AAM), F(IDSA)  
Cepheid  
USA

David Warshauer, PhD, D(ABMM)  
Wisconsin State Laboratory of  
Hygiene  
USA

Adrian M. Zelazny, PhD,  
D(ABMM)  
USA

### Staff

Clinical and Laboratory Standards  
Institute  
USA

Marcy L. Hackenbrack, MCM,  
M(ASCP)  
*Project Manager*

Megan L. Tertel, MA, ELS  
*Editorial Manager*

Catherine E.M. Jenkins  
*Editor*

Kristy L. Leirer, MS  
*Editor*

Laura Martin  
*Editor*

## Acknowledgment for the Expert Panel on Microbiology

CLSI, the Consensus Council, and the Document Development Committee on Laboratory Detection and Identification of Mycobacteria gratefully acknowledge the Expert Panel on Microbiology for serving as technical advisors and subject matter experts during the development of this guideline.

### Expert Panel on Microbiology

**Richard B. Thomson, Jr., PhD,  
D(ABMM), FAAM  
Chairholder**  
Evanston Hospital, NorthShore  
University HealthSystem  
USA

**Jean B. Patel, PhD, D(ABMM)  
Vice-Chairholder**  
Centers for Disease Control and  
Prevention  
USA

Kevin Alby, PhD, D(ABMM)  
University of Pennsylvania Health  
System  
USA

Lynette Y. Berkeley, PhD, MT(ASCP)  
FDA Center for Drug Evaluation and  
Research  
USA

Carey-Ann Burnham, PhD, D(ABMM)  
Washington University School of Medicine  
USA

Karissa Culbreath, PhD, D(ABMM)  
TriCore Reference Laboratories  
USA

German Esparza, BSc  
Proasecal LTD  
Colombia

Margie Morgan, PhD, D(ABMM)  
Cedars-Sinai Medical Center  
USA

Mark G. Papich, DVM, MS  
College of Veterinary Medicine,  
North Carolina State University  
USA

David H. Pincus, MS,  
RM/SM(NRCM), SM(ASCP)  
bioMérieux, Inc.  
USA

Audrey N. Schuetz, MD, MPH,  
D(ABMM)  
Mayo Clinic  
USA

Ribhi M. Shawar, PhD,  
D(ABMM)  
FDA Center for Devices and  
Radiological Health  
USA

### Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Laboratory Detection and Identification of Mycobacteria gratefully acknowledge the following volunteers for their important contributions to the development of this guideline:

Sanchita Das, MD, D(ABMM)  
NorthShore University HealthSystem  
USA

Meenu K. Sharma, PhD  
Canadian Science Center for Human and  
Animal Health  
Canada

## Contents

Abstract .....	i
Committee Membership .....	iii
Foreword .....	vii
Chapter 1: Introduction .....	1
1.1 Scope .....	1
1.2 Background .....	1
1.3 Standard Precautions .....	2
1.4 Terminology .....	2
Chapter 2: Safety and Risk Assessment .....	5
2.1 Biosafety Levels .....	5
2.2 Biosafety Measures for Mycobacteriology Laboratories .....	8
Chapter 3: Clinical Significance of Mycobacteria .....	11
3.1 <i>Mycobacterium tuberculosis</i> complex .....	11
3.2 Nontuberculous Mycobacteria .....	11
Chapter 4: Process for Laboratory Diagnosis of Mycobacteria .....	15
4.1 Mycobacteria Detection and Identification Process Flow Chart .....	15
4.2 Specimen Types, Collection, Transport, and Storage .....	17
4.3 Specimen Processing .....	23
4.4 Direct Mycobacteria Detection .....	24
4.5 Mycobacteria Detection by Culture .....	33
Chapter 5: Mycobacterial Identification .....	43
5.1 Phenotypic Methods .....	44
5.2 Rapid Identification of <i>M. tuberculosis</i> complex With Immunochromatography .....	49
5.3 Genotypic Identification Methods .....	49
Chapter 6: Quality Systems: Essentials of Process Management .....	53
6.1 Quality Control .....	53
6.2 Monitoring Consistency of Specimen Processing and Mycobacteria Isolation .....	53
Chapter 7: Conclusion .....	62
Chapter 8: Supplemental Information .....	62
References .....	63
Additional Resources .....	72
Appendix A. Digestion, Decontamination, and Concentration Methods .....	73
Appendix B. Staining Procedures .....	79
Appendix C. Collecting Performance Parameters for Periodic Routine Monitoring of Internal Quality Control Indicators for Mycobacteria Specimens ( <i>M. tuberculosis</i> complex and Nontuberculous Mycobacteria) .....	84
Appendix D. Preparing and Storing Quality Control Organisms .....	86
The Quality Management System Approach .....	88
Related CLSI Reference Materials .....	89

This is a preview of "CLSI M48-Ed2". [Click here to purchase the full version from the ANSI store.](#)



## Foreword

Tuberculosis (TB) is a serious global disease, with approximately 9.6 million cases worldwide. In 2014, it was estimated that 1.5 million deaths from TB occur each year.<sup>1</sup> During the past decade, much progress has been made in controlling spread through implementation of TB control programs along with directly observed, short-course treatment.

Since M48 was last published in 2008, an increase in nontuberculous mycobacteria (NTM) infections has added to the significant worldwide TB problem. In 1975, the genus *Mycobacterium* encompassed approximately 30 known species. As of 2018, it includes more than 170.<sup>2</sup> Newer laboratory methods for mycobacteria identification have uncovered many new species not previously identified by traditional phenotypic and biochemical methods, and the abundance of species poses an additional challenge to the mycobacteriology laboratory for providing timely diagnoses.

The medical microbiology laboratory plays an important role in patient care and public health. To reduce TB transmission, laboratory TB diagnosis must be optimized and accelerated for better patient management and implementation of appropriate infection control and public health measures. The document development committee recognizes the increasing complexity of these laboratory methods, as well as other significant demands on the laboratory (eg, turnaround time for reporting). Therefore, this edition of M48 focuses particular attention on providing a consensus guideline for medical laboratories to achieve the optimal approach for diagnosing mycobacterial infections, regardless of available resources.

Essential safety aspects are discussed in this guideline, with an emphasis on specific practices for the mycobacteriology laboratory. Because many laboratories do not have the appropriate technologies and resources for optimal diagnosis of mycobacterial infections, referral services are recommended. A table describing appropriate collection, transport, and storage conditions for various specimen types is included, because these aspects are important for successfully isolating mycobacteria from patient specimens. Optimal methods for specimen processing, direct detection, and mycobacterial culture are also provided. Important laboratory issues and concerns, such as contamination, QC, and quality assurance, are discussed. Finally, current methods for mycobacterial identification are provided. Although this guideline's primary focus is the diagnosis of active *Mycobacterium tuberculosis* infections, the NTM are also discussed in terms of clinical significance and optimal laboratory methods for detection, culture, and identification. The relative clinical importance of any given NTM and the considerations regarding the isolate's clinical significance are discussed.

## Overview of Changes

This guideline replaces the previous edition of the approved guideline, M48-A, published in 2008. Several changes were made in this edition, including:

- Reorganized to fit the CLSI quality management system and path of workflow format
- Removed information on service levels for mycobacteriology laboratory services
- Revised the safety and risk assessment chapter
- Expanded the review of the clinically significant NTM isolates from various patient specimens to reflect the significant increase in the number of different species and emerging roles in various clinical settings
- Expanded the discussion and review of the role of nucleic acid amplification tests for detecting *Mycobacterium tuberculosis* complex directly in patient specimens

- Described the method for determining contamination rates for mycobacterial culture
- Removed information on conventional biochemical tests and high-performance liquid chromatography, because these methods are no longer recommended for mycobacterial identification
  - Other conventional phenotypic tests such as growth rate on subculture to solid mycobacterial media, pigment production, and colony morphology were retained, because these tests remain essential for accurate identification of some mycobacterial species.
- Added guidance for using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for mycobacterial identification
- Expanded the discussion of molecular sequencing methods for mycobacterial identification
- Developed an algorithm for mycobacterial identification using different methods
- Added a subchapter discussing the collection of performance parameters for monitoring internal QC indicators

**NOTE:** The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

### **Key Words**

Acid-fast bacilli, mycobacteria, *Mycobacterium tuberculosis*, nontuberculous (or non-*M. tuberculosis*) mycobacteria, tuberculosis

# Laboratory Detection and Identification of Mycobacteria

## Chapter 1: Introduction

This chapter includes:

- Guideline's scope and applicable exclusions
- Background information pertinent to the guideline's content
- Standard precautions information
- "Note on Terminology" that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the guideline
- Abbreviations and acronyms used in the guideline

### 1.1 Scope

This guideline provides recommendations for laboratories on the total testing process for patients with suspected mycobacterial infections. Recommendations are provided for patient specimen collection, preservation, and transport. Procedures for detecting mycobacteria directly in specimens using microscopy and amplification techniques, optimal recovery of mycobacteria from patient specimens, and identification of mycobacterial species by traditional (phenotypic) and alternative (phenotypic and genotypic) laboratory methods are discussed. Mycobacterial susceptibility testing is not included in this guideline and is covered in CLSI document M24.<sup>3</sup>

This guideline is intended for medical and public health laboratories performing procedures for identifying mycobacteria from patient specimens. However, many chapters of this guideline, especially those related to identification methods, are intended for full-service mycobacteriology laboratories in industrialized countries. It is recognized that providing various laboratory services depends on existing local conditions and resources. For many laboratories in tuberculosis (TB)-endemic countries, implementing quality-assured, direct sputum smear microscopy may be a higher priority than the more equipment- and reagent-dependent methods described. Additional information for such laboratories is publicly available from the World Health Organization (WHO) and other scientific and public health organizations. However, these guidelines should provide useful information for international laboratories providing or planning to provide services beyond microscopy, such as solid media culture or rapid methods for *Mycobacterium tuberculosis* complex (MTBC) detection.

### 1.2 Background

Since M48 was last published in 2008, laboratory diagnosis of TB and nontuberculous mycobacterial (NTM) infections has drastically changed. Numerous laboratory assays have been introduced to rapidly and more accurately diagnose these infections. Strategies optimizing the evaluation and implementation of these new assays have also undergone numerous changes that affect various laboratory settings and are no longer "one size fits all." These new developments, including new assays or laboratory practice strategies, were considered when revising this guideline.